Under construction – not a live service
Sign in

2025-523620-44-02RecruitingPhase 4

BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology

Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Jan 2026

Next steps

Brief summary (registry, in English)

In this study, we aim to investigate the cardiovascular side effects of immune checkpoint inhibitors.

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
1000 (estimated)
First submitted
26 Oct 2025
Start date
20 Jan 2026
Lead sponsor
Semmelweis University
EU CT number
2025-523620-44-02

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 1000
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer who are planning to start immune checkpoint inhibitor therapy. It studies the side effects on the heart and blood vessels.

Age
At least 18 years old.
Sex
All sexes can join.
Earlier treatment
Immune checkpoint inhibitor therapy must be planned.

Main reasons for not taking part

  • No signed informed consent
  • Under 18 years of age
  • Cannot read or write (illiteracy)
  • Pregnancy or breastfeeding

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Age

  • Age under 18

Other

  • Lack of informed consent form
  • Illiteracy
  • Pregnancy and breastfeeding

Who the study is looking for

  • Patients presented to the oncology teams of Semmelweis University and clinics in the country wishing to join the research
  • Planned immune checkpoint inhibitor therapy
  • At least 18 years of age
  • Signing of the patient information sheet and consent form by the patient
  • Accessible medical history

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Semmelweis UniversityBudapest VIIIHungaryRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.